CatalystLawGroup 4330 La Jolla Village Drive, Suite 220, San Diego, CA 92122 • phone: 858-450-0099 • www.catalystlaw.com

energizing the business of science



October 11, 2004

_[[/EV383801504US]

0

 $\langle \rangle$

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being is being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage for Express Mail EV 38301504 US in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450:

Date of Deposit

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: New Aminoglycoside Antibiotics as Novel Anti-Infective Agents

Application No.: 10/606,700 Our Docket No.: 8024-004-US

Dear Sir or Madam:

In response to the Office Action of the above-referenced Non Provisional Application, mailed on June 26, 2003, enclosed please find the following:

- 1. Transmittal Form PTO/SB/21 (1 page);
- 2. Response To Restriction Requirement (3 pages);
- 3. Copy of Office Action Summary (4 pages); and
- 4. Self-addressed, stamped postcard.

The self-addressed, stamped postcard has been included for your convenience. After confirming receipt of these documents please return the postcard to us at your earliest convenience. Should you have any questions, please do not hesitate to contact me by phone at (858) 450-0099.

Sincerely yours.

Jeff Landes, Esq. Reg. No. 55,355





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INV	ENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.	
10/606,700	10/606,700 06/26/2003		Chang-Hsing Liang		8024-004-US	5029	
32301	7590	. 09/17/2004			EXA	MINER	
CATALYST LAW GROUP, APC 4330 LA JOLLA VILLAGE DRIVE SUITE 220 SAN DIEGO, CA 92122					PESELEV, ELLI		
					ART UNIT	PAPER NUMBER	
SAN DIEGO), CR 92122				1623		

DATE MAILED: 09/17/2004

Due 1/04

Please find below and/or attached an Office communication concerning this application or proceeding.

1 ig	OIPE							
		Application No.	Applicant(s)					
	(OCT 1 2 2004 (L)	10/606,700	LIANG ET AL.					
	Office Action Summary	Examiner	Art Unit					
	77.40E-43W	Eili Peselev	1623					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
		/ IS SET TO EXPIRE 1	MONTH(S) FROM					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Fallure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
. 1)□	Responsive to communication(s) filed on							
2a)□								
.3)□								
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
	4) Claim(s) 1-8 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
•	Claim(s) is/are allowed.							
	Claim(s) is/are rejected.							
	☐ Claim(s) is/are objected to. ☑ Claim(s) <u>1-8</u> are subject to restriction and/or election requirement.							
o/M Claim(s) 1-0 are subject to restriction and/or election requirements								
Applicat	lon Papers							
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 								
3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)								
2) 🔲 Noti	ice of Draftsperson's Patent Drawing Review (PTO-948)	Paper	No(s)/Mail Date					
3) 🔲 Info	rmation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 per No(s)/Mail Date	, —	e of Informal Patent Application (PTO-152)					
, ap			<u> </u>					

Application/Control Number: 10/606,700

Art Unit: 1623

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1, 2 and 5-8, drawn to aminoglycosides, classified in class 536, subclass 17.2.

II. Claims 3-4, drawn to cyclohexyl derivatives, classified in class 564, subclass 1+.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). In the instant case, the intermediate product is deemed to be useful as insecticide and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/606,700

Art Unit: 1623

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 9.00-5.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ELLI PESELEV
PRIMARY EXAMINER
GROUP 1800